Company Highlights Proprietary DehydraTECH platform improves oral bioavailability and tolerability of active pharmaceutical ingredients (APIs), including GLP-1 drugs 65 patents granted globally across multiple sectors, with more awaiting Positive human and preclinical study results demonstrating improved absorption and reduced side effects in GLP-1 drug formulations Positioned to capitalize on rapid growth in oral GLP-1 treatments following recent FDA approvals, including Novo Nordisks Wegovy pill and Eli Lillys Foundayo Key Project DehydraTECH is Lexarias core technology, a patented formulation and processing platform that enhances oral drug delivery
Then, you can take the prescription to a pharmacy to have it filled
The messenger RNA expression levels of the (A) SREBP-2, (B) ACAT1, (C) HMGCR, (D) SQLE, (E) LXR, (F) CYP7A1, (G) LDLR, and (H) PCSK9 genes were analyzed with quantitative real-time polymerase chain reaction and normalized to that of the ACTB gene
Cellular & molecular immunology
